Fresh savings just popped up! 25% off 3 or more products. | Start Saving >>
β-Amyloid (pE3 Peptide) Antibody

β-Amyloid (pE3 Peptide) Antibody #13172

This product is discontinued

We recommend the following alternatives

  • WB
  • IHC
  • IF
Dot Blot-Peptide

β-Amyloid (pE3 Peptide) Antibody specificity is demonstrated using peptide dot blot. β-Amyloid (pE3 Peptide) Antibody binds to pre-coated β-amyloid (pE3) peptide but not to β-amyloid (E3) peptide or scrambled β-amyloid (pE3) peptide.

Learn more about how we get our images

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

β-Amyloid (pE3 Peptide) Antibody recognizes recombinant pE3 form of β-amyloid peptides. This antibody does not cross-react with the non-pyroglutamate (E3) form of β-amyloid peptides.

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human β-amyloid (pE3) peptide. Antibodies are purified by protein A and peptide affinity chromatography.

Amyloid β (Aβ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). The extracellular deposition and accumulation of the released Aβ fragments form the main components of amyloid plaques in Alzheimer's disease (1). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (2-5). Phosphorylation at Thr668 (a position corresponding to the APP695 isoform) by cyclin-dependent kinase is cell-cycle dependent and peaks during G2/M phase (4). APP phosphorylated at Thr668 exists in adult rat brain and correlates with cultured neuronal differentiation (5,6).

Aβ peptides can be further modified by amino-terminal truncation that exposes a free glutamate residue to the enzyme glutaminyl cyclase, which catalyzes the formation of an amino-terminal pyroglutamate (pE) (7,8). Aβ (pE3) peptides exhibit increased stability relative to non-modified peptides due to an enhanced resistance to peptidase-mediated degradation (9) and a higher propensity to form β-sheets and aggregate (10). Antibodies targeting Aβ (pE3) peptides may be plaque-specific as there is no evidence for circulating Aβ (pE3) peptides (11).

  1. Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
  2. Caporaso, G.L. et al. (1992) Proc Natl Acad Sci USA 89, 3055-9.
  3. Hung, A.Y. and Selkoe, D.J. (1994) EMBO J 13, 534-42.
  4. Suzuki, T. et al. (1994) EMBO J 13, 1114-22.
  5. Ando, K. et al. (1999) J Neurosci 19, 4421-7.
  6. Iijima, K. et al. (2000) J Neurochem 75, 1085-91.
  7. Jawhar, S. et al. (2011) J Biol Chem 286, 38825-32.
  8. Saido, T.C. et al. (1995) Neuron 14, 457-66.
  9. Saido, T.C. et al. (1996) Neurosci Lett 215, 173-6.
  10. He, W. and Barrow, C.J. (1999) Biochemistry 38, 10871-7.
  11. Demattos, R.B. et al. (2012) Neuron 76, 908-20.
Entrez-Gene Id
Swiss-Prot Acc.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.

Upstream / Downstream


Explore pathways related to this product.